PHOEBE Update Demonstrates OS Benefit For Pyrotinib Plus Capecitabine
From 2021 San Antonio Breast Cancer Symposium:
Latest overall survival findings from the PHOEBE trial support the use of pyrotinib plus capecitabine for second-line care of patients with HER2-positive metastatic breast cancer